Publications

• Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
  N Engl J Med Volume: 391 Page(s): 1379 - 1389
  10/17/2024 Authors: Herrera AF; LeBlanc M; Castellino SM; Li H; Rutherford SC; Evens AM; Davison K; Punnett A; Parsons SK; Ahmed S
• Randomized study of induction with bendamustine-rituximab bortezomib and maintenance with rituximab lenalidomide for MCL.
  Blood Volume: 144 Page(s): 1083 - 1092
  09/05/2024 Authors: Smith MR; Jegede OA; Martin P; Till BG; Parekh SS; Yang DT; Hsi ED; Witzig T; Dave S; Scott D
• Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.
  Blood Adv Volume: 8 Page(s): 1464 - 1468
  03/26/2024 Authors: Rutherford SC; Yin J; Pederson LD; Blum KA; Martin P; Jung S-H; Grant B; Rosenbaum C; Cheson BD; Bartlett NL
• A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.
  Haematologica Volume: 109 Page(s): 953 - 957
  03/01/2024 Authors: Fehniger TA; Watkins MP; Ezenwajiaku N; Wan F; Hurd DD; Cashen AF; Blum KA; Goy A; Fenske TS; Wagner-Johnston ND
• Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.
  Blood Adv Volume: 7 Page(s): 7295 - 7303
  12/12/2023 Authors: Desai SH; Spinner MA; Evens AM; Sykorova A; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP
• Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
  Blood Adv Volume: 7 Page(s): 2287 - 2296
  06/13/2023 Authors: Epperla N; Switchenko J; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Mathews S; Burkart M
• 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
  Hematol Oncol Volume: 41 Suppl 2 Page(s): 597 - 598
  06/01/2023 Authors: Bond DA; Wei L; Yildiz V; Reneau J; Sawalha Y; Christian B; Brammer J; Epperla N; Koff J; Dendorfer A
• 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
  Hematol Oncol Volume: 41 Suppl 2 Page(s): 33 - 35
  06/01/2023 Authors: Herrera AF; LeBlanc M; Castellino SM; Li H; Rutherford SC; Evens AM; Davison K; Punnett A; Hodgson D; Parsons SK
• A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
  Cancers (Basel) Volume: 15
  02/24/2023 Authors: Hanel W; Shindiapina P; Bond DA; Sawalha Y; Epperla N; Voorhees T; Welkie RL; Huang Y; Behbehani GK; Zhang X
• Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).
  J Clin Oncol Volume: 41 Page(s): 1023 - 1034
  02/10/2023 Authors: LaCasce AS; Dockter T; Ruppert AS; Kostakoglu L; Schder H; Hsi E; Bogart J; Cheson B; Wagner-Johnston N; Abramson J
• Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
  J Clin Oncol Volume: 41 Page(s): 336 - 342
  01/10/2023 Authors: Rutherford SC; Yin J; Pederson L; Perez Burbano G; LaPlant B; Shadman M; Li H; LeBlanc ML; Kenkre VP; Hong F
• Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
  Cancer Res Commun Volume: 2 Page(s): 1684 - 1692
  12/01/2022 Authors: Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA
• Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.
  Clin Lymphoma Myeloma Leuk Volume: 22 Page(s): e1009 - e1018
  11/01/2022 Authors: Dixon JG; alayan ; Chihara D; Nielsen T; Dimier N; Zheng J; Wall AK; Salles G; Morschhauser F; Marcus R
• CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S281 - S282
  10/01/2022 Authors: Chang A; Lai L; Akhtar A; Linderman S; Orellana-Noia V; Saini M; Valanparambil R; Blum K; Allen P; Lechowicz M
• Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
  J Clin Oncol Volume: 40 Page(s): 3020 - 3031
  09/30/2022 Authors: Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM
• A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
  Cancer Res Commun Volume: 2 Page(s): 795 - 805
  08/01/2022 Authors: Blum KA; Supko JG; Maris MB; Flinn IW; Goy A; Younes A; Bobba S; Senderowicz AM; Efuni S; Rippley R
• A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
  Leuk Lymphoma Volume: 63 Page(s): 1750 - 1753
  07/01/2022 Authors: Bond DA; Huang Y; Christian BA; Jaglowski S; Benson D; Alinari L; Baiocchi RA; Cohen JB; Blum KA; Maddocks KJ
• End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
  Br J Haematol Volume: 198 Page(s): 333 - 337
  07/01/2022 Authors: Dixon JG; Dimier N; Nielsen T; Zheng J; Marcus R; Morschhauser F; Evens AM; Federico M; Blum KA; Shi Q
• A Phase I Study of Apolizumab, an Anti-HLA-DR -chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies.
  Am J Clin Oncol Volume: 45 Page(s): 294 - 297
  07/01/2022 Authors: Fracasso PM; Goodner SA; Wildi JD; Naughton MJ; Linette GP; Govindan R; Tan BR; Blum KA; Jones GJ; Pearce TE
• Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.
  Blood Adv Volume: 6 Page(s): 2745 - 2756
  05/10/2022 Authors: Harkins RA; Patel SP; Lee MJ; Switchenko JM; Ansell SM; Bartlett NL; Blum KA; Cashen AF; Casulo C; Friedberg JW
• Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.
  Blood Adv Volume: 5 Page(s): 5179 - 5189
  12/14/2021 Authors: Bond DA; Switchenko JM; Villa D; Maddocks K; Churnetski M; Gerrie AS; Goyal S; Shanmugasundaram K; Calzada O; Kolla B
• Controversies in the management of early-stage Hodgkin lymphoma.
  Hematology Am Soc Hematol Educ Program Volume: 2021 Page(s): 234 - 239
  12/10/2021 Authors: Blum KA
• Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
  Am J Hematol Volume: 96 Page(s): 1374 - 1384
  11/01/2021 Authors: Karmali R; Switchenko JM; Goyal S; Shanmugasundaram K; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ
• Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
  Eur J Haematol Volume: 107 Page(s): 301 - 310
  09/01/2021 Authors: Shanmugasundaram K; Goyal S; Switchenko J; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ
• HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
  Blood Adv Volume: 5 Page(s): 2852 - 2862
  07/27/2021 Authors: Alderuccio JP; Olszewski AJ; Evens AM; Collins GP; Danilov AV; Bower M; Jagadeesh D; Zhu C; Sperling A; Kim S-H
• Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
  Haematologica Volume: 106 Page(s): 1932 - 1942
  07/01/2021 Authors: Zayac AS; Evens AM; Danilov A; Smith SD; Jagadeesh D; Leslie LA; Wei C; Kim S-H; Naik S; Sundaram S
• Burkitt Lymphoma International Prognostic Index.
  J Clin Oncol Volume: 39 Page(s): 1129 - 1138
  04/01/2021 Authors: Olszewski AJ; Jakobsen LH; Collins GP; Cwynarski K; Bachanova V; Blum KA; Boughan KM; Bower M; Dalla Pria A; Danilov A
• Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
  Blood Volume: 137 Page(s): 374 - 386
  01/21/2021 Authors: Evens AM; Danilov A; Jagadeesh D; Sperling A; Kim S-H; Vaca R; Wei C; Rector D; Sundaram S; Reddy N
• Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
  Volume: 136
  11/05/2020 Authors: Santapuram PR; Rupji M; Graiser M; Waller EK; Blum KA; Allen PB; Koff JL; Heffner L; Lechowicz MJ; Lonial S
• Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma
  Volume: 136
  11/05/2020 Authors: Greenwell IB; Switchenko JM; Maddocks KJ; Kahl BS; Craig AFM; Alizadeh AA; Allen PB; Marbury AL; Escobar A; Valla K
• Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis
  Volume: 136
  11/05/2020 Authors: Alderuccio JP; Olszewski AJ; Evens AM; Collins GP; Danilov A; Bower M; Jagadeesh D; Zhu C; Sperling A; Kim S-H
• The Burkitt Lymphoma International Prognostic Index (BL-IPI)
  Volume: 136
  11/05/2020 Authors: Olszewski AJ; Jakobsen LH; Collins GP; Cwynarski K; Bachanova V; Blum KA; Boughan KM; Bower M; Pria AD; Danilov A
• Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
  Clin Cancer Res Volume: 26 Page(s): 3918 - 3927
  08/01/2020 Authors: Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA
• Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.
  Am J Hematol Volume: 95 Page(s): 583 - 593
  06/01/2020 Authors: Kaplan LD; Maurer MJ; Stock W; Bartlett NL; Fulton N; Pettinger A; Byrd JC; Blum KA; LaCasce AS; Hsi ED
• Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
  Lancet Haematol Volume: 7 Page(s): e490 - e497
  06/01/2020 Authors: Thanarajasingam G; Leonard JP; Witzig TE; Habermann TM; Blum KA; Bartlett NL; Flowers CR; Pitcher BN; Jung S-H; Atherton PJ
• Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
  Cancer Volume: 126 Page(s): 1235 - 1242
  03/15/2020 Authors: Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM
• Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq
  Volume: 134
  11/13/2019 Authors: Di Liberto M; Hu Y; Huang X; Lee CY; Wang K; Bartlett NL; Ridling L; Blum KA; Maddocks KJ; Park SI
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Volume: 134
  11/13/2019 Authors: Cohen JB; Switchenko JM; Shanmugasundaram K; Goyal S; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK
• The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma
  Volume: 134
  11/13/2019 Authors: Romancik J; Switchenko JM; Shanmugasundaram K; Goyal S; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK
• A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma
  Volume: 134
  11/13/2019 Authors: Bond DA; Yildiz V; Wei L; Alinari L; William BM; Brammer JE; Christian BA; Blum KA; Maddocks KJ
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Volume: 134
  11/13/2019 Authors: Epperla N; Switchenko JM; Shanmugasundaram K; Goyal S; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK
• Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
  Cancer Volume: 125 Page(s): 3378 - 3389
  10/01/2019 Authors: Blum KA; Polley M-Y; Jung S-H; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD
• Martin P, Bartlett NL, Blum KA, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133(11):1201-1204.
  Blood Volume: 134 Page(s): 908
  09/12/2019
• Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
  J Clin Oncol Volume: 37 Page(s): 1790 - 1799
  07/20/2019 Authors: Bartlett NL; Wilson WH; Jung S-H; Hsi ED; Maurer MJ; Pederson LD; Polley M-YC; Pitcher BN; Cheson BD; Kahl BS
• Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
  Br J Clin Pharmacol Volume: 85 Page(s): 924 - 934
  05/01/2019 Authors: Hughes JH; Phelps MA; Upton RN; Reuter SE; Gao Y; Byrd JC; Grever MR; Hofmeister CC; Marcucci G; Blum W
• A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
  Volume: 133 Page(s): 1201 - 1204
  03/14/2019 Authors: Martin P; Bartlett NL; Blum KA; Park S; Maddocks K; Ruan J; Ridling L; Dittus C; Chen Z; Huang X
• Prognostic Variables of Progression Free Survival in Mantle Cell Lymphoma after Autologous Stem Cell Transplantation
  Volume: 25
  03/01/2019 Authors: Churnetski MC; Switchenko JM; Goyal S; Shanmugasundaram K; Calzada O; Kolla B; Bachanova V; Gerson JN; Barta SK; Maldonado E
• Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.
  Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): e123 - e128
  03/01/2019 Authors: Bond DA; Dotson E; Awan FT; Baiocchi RA; Blum KA; Maddocks K
• The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.
  Cancer Med Volume: 8 Page(s): 165 - 173
  01/01/2019 Authors: Lansigan F; Barak I; Pitcher B; Jung S-H; Cheson BD; Czuczman M; Martin P; Hsi E; Schder H; Smith S
• Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.
  Leuk Lymphoma Volume: 59 Page(s): 2862 - 2870
  12/01/2018 Authors: Calzada O; Switchenko JM; Maly JJ; Blum KA; Grover N; Mathews S; Park SI; Gordon M; Danilov A; Epperla N
• Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)
  Volume: 132
  11/29/2018 Authors: Kaplan LD; Maurer MJ; Stock W; Bartlett NL; Fulton N; Pettinger A; Byrd JC; Blum KA; LaCasce AS; Hurd DD
• Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States.
  Br J Haematol Volume: 183 Page(s): 385 - 399
  11/01/2018 Authors: Blum KA; Keller FG; Castellino S; Phan A; Flowers CR
• Pharmacodynamic assessment in whole blood for the BET bromodomain inhibitor CPI-0610 of target engagement in patients with progressive lymphoma
  Volume: 78
  07/01/2018 Authors: Mertz JA; Blum KA; Younes A; Abramson JS; Maris MB; Flinn IW; Goy A; Borger DR; Cooper MR; Sims RJ
• Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
  Cancer Volume: 124 Page(s): 2306 - 2315
  06/01/2018 Authors: Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ
• Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
  Volume: 36
  05/20/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff JL; Gupta VA; Lechowicz MJ; Nooka AK; Kaufman JL; Lonial S; Waller EK
• Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  Ann Oncol Volume: 29 Page(s): 1266 - 1272
  05/01/2018 Authors: Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S
• Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
  JAMA Oncol Volume: 4 Page(s): 712 - 716
  05/01/2018 Authors: O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M
• Single-agent ibrutinib in treatment-nave and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
  Blood Volume: 131 Page(s): 1910 - 1919
  04/26/2018 Authors: O'Brien S; Furman RR; Coutre S; Flinn IW; Burger JA; Blum K; Sharman J; Wierda W; Jones J; Zhao W
• Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
  Leuk Lymphoma Volume: 59 Page(s): 888 - 895
  04/01/2018 Authors: Guidot DM; Switchenko JM; Nastoupil LJ; Koff JL; Blum KA; Maly J; Flowers CR; Cohen JB
• Treatment-Resistant Hodgkin Lymphoma: Defining the Role of Autologous Transplantation.
  Cancer J Volume: 24 Page(s): 244 - 248
  01/01/2018 Authors: Blum KA
• Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
  Blood Adv Volume: 1 Page(s): 2600 - 2609
  12/12/2017 Authors: Pilichowska M; Pittaluga S; Ferry JA; Hemminger J; Chang H; Kanakry JA; Sehn LH; Feldman T; Abramson JS; Kritharis A
• Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers
  Volume: 130
  12/07/2017 Authors: Evens AM; Pilichowska M; Pittaluga S; Ferry J; Hemminger J; Chang H; Kanakry JA; Sehn LH; Feldman TA; Hernandez-Ilizaliturri FJ
• Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
  Br J Haematol Volume: 179 Page(s): 739 - 747
  12/01/2017 Authors: Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B
• A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
  Ann Oncol Volume: 28 Page(s): 2806 - 2812
  11/01/2017 Authors: Martin P; Jung S-H; Pitcher B; Bartlett NL; Blum KA; Shea T; Hsi ED; Ruan J; Smith SE; Leonard JP
• Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.
  Blood Adv Volume: 1 Page(s): 1739 - 1748
  09/12/2017 Authors: Wiczer TE; Levine LB; Brumbaugh J; Coggins J; Zhao Q; Ruppert AS; Rogers K; McCoy A; Mousa L; Guha A
• Association of Complex Karyotype with Inferior Survival in Mantle Cell Lymphoma is Independent of Specific Cytogenetic Abnormalities
  Volume: 17 Page(s): S377 - S377
  09/01/2017 Authors: Greenwell IB; Staton AD; Lee M; Switchenko JM; Maly J; Blum K; Grover N; Mathews S; Park S; Gordon M
• A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
  Leuk Lymphoma Volume: 58 Page(s): 1 - 2
  09/01/2017 Authors: Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
• Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.
  Blood Adv Volume: 1 Page(s): 1584 - 1588
  08/22/2017 Authors: Miller CR; Ruppert AS; Heerema NA; Maddocks KJ; Labanowska J; Breidenbach H; Lozanski G; Zhao W; Gordon AL; Jones JA
• Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
  J Clin Oncol Volume: 35 Page(s): 2260 - 2267
  07/10/2017 Authors: Landsburg DJ; Falkiewicz MK; Maly J; Blum KA; Howlett C; Feldman T; Mato AR; Hill BT; Li S; Medeiros LJ
• Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
  Leuk Lymphoma Volume: 58 Page(s): 1589 - 1597
  07/01/2017 Authors: Bond DA; Huang Y; Ruppert AS; Walker AR; Dotson EK; Roddy J; Blum KA; Christian BA
• A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.
  Clin Lymphoma Myeloma Leuk Volume: 17 Page(s): 347 - 353
  06/01/2017 Authors: Maly JJ; Christian BA; Zhu X; Wei L; Sexton JL; Jaglowski SM; Devine SM; Fehniger TA; Wagner-Johnston ND; Phelps MA
• Association of FDG PET-CT (PET) avid skeletal lesions (SL) with progression-free survival (PFS) in patients (pts) with previously untreated follicular lymphoma (FL).
  Volume: 35
  05/20/2017 Authors: Maly JJ; Wei L; Hemminger J; Christian B; Maddocks KJ; Jones JA; Wright C; Blum KA
• BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
  J Clin Oncol Volume: 35 Page(s): 1437 - 1443
  05/01/2017 Authors: Woyach JA; Ruppert AS; Guinn D; Lehman A; Blachly JS; Lozanski A; Heerema NA; Zhao W; Coleman J; Jones D
• Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
  J Natl Compr Canc Netw Volume: 15 Page(s): 608 - 638
  05/01/2017 Authors: Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Aoun P; Bello CM; Benitez CM; Bernat K; Bierman PJ; Blum KA
• Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.
  Haematologica Volume: 102 Page(s): e156 - e159
  04/01/2017 Authors: Salles G; Schuster SJ; de Vos S; Wagner-Johnston ND; Viardot A; Blum KA; Flowers CR; Jurczak WJ; Flinn IW; Kahl BS
• Outcomes in Mantle Cell Lymphoma for Elderly Patients Undergoing Autologous Stem Cell Transplant in CR1
  Volume: 23 Page(s): S215 - S216
  03/01/2017 Authors: Greenwell IB; Valla K; Caulfield S; Switchenko JM; Staton A; Flowers C; Maly J; Blum KA; Grover N; Mathews S
• RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
  Br J Haematol Volume: 176 Page(s): 759 - 769
  03/01/2017 Authors: Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA
• Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
  Clin Cancer Res Volume: 23 Page(s): 1149 - 1155
  03/01/2017 Authors: Coutr SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA
• Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
  Expert Rev Anticancer Ther Volume: 17 Page(s): 271 - 279
  03/01/2017 Authors: Greenwell IB; Flowers CR; Blum KA; Cohen JB
• Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity
  Volume: 128
  12/02/2016 Authors: Landsburg DJ; Reddy N; Howlett C; Feldman T; Mato AR; Kaplan JB; Behdad A; Petrich AM; Maly J; Blum K
• Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study
  Volume: 128
  12/02/2016 Authors: Evens AM; Pilichowska M; Pittaluga S; Ferry J; Hemminger J; Kanakry JA; Sehn LH; Feldman T; Abramson JS; Hernandez-Ilizaliturri FJ
• Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance)
  Volume: 128
  12/02/2016 Authors: Lansigan F; Barak I; Pitcher BN; Jung S-H; Cheson B; Czuczman MS; Grant BW; Martin P; Hsi ED; Schoder H
• a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
  Volume: 128
  12/02/2016 Authors: Maddocks KJ; Cohen JB; Huang Y; Christian BA; Benson DM; Jones J; Flowers C; Heffner LT; Jenkins C; Sexton J
• PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy
  Volume: 128
  12/02/2016 Authors: Di Liberto M; Huang X; Elemento O; Eng K; Blum KA; Bartlett NL; Park SI; Ruan J; Maddocks KJ; Inghirami G
• Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics
  Volume: 128
  12/02/2016 Authors: Staton AD; Greenwell IB; Switchenko JM; Maly J; Blum K; Grover NS; Mathews S; Park SI; Gordon MJ; Danilov AV
• Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy
  Volume: 128
  12/02/2016 Authors: Pavlik A; Barr H; Dotson E; Byrd JC; Blum KA; Awan FT; Woyach JA; Maddocks KJ; Christian BA; Jones J
• Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.
  J Natl Cancer Inst Volume: 108
  12/01/2016 Authors: Nowakowski GS; Blum KA; Kahl BS; Friedberg JW; Baizer L; Little RF; Maloney DG; Sehn LH; Williams ME; Wilson WH
• Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
  Volume: 128 Page(s): 2510 - 2516
  11/24/2016 Authors: Ujjani CS; Jung S-H; Pitcher B; Martin P; Park SI; Blum KA; Smith SM; Czuczman M; Davids MS; Levine E
• Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
  Br J Haematol Volume: 175 Page(s): 631 - 640
  11/01/2016 Authors: Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA
• Subgroup analyses of diffuse large B-cell lymphoma and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL)
  Volume: 39 Page(s): 72 - 72
  10/01/2016 Authors: Buske C; Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Ambarkhane S
• De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
  Am J Hematol Volume: 91 Page(s): 395 - 399
  06/01/2016 Authors: Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F
• SUBGROUP ANALYSES OF DIFFUSE LARGE B-CELL LYMPHOMA AND INDOLENT LYMPHOMA COHORTS FROM A PHASE IIA STUDY OF SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
  Volume: 101 Page(s): 317 - 317
  06/01/2016 Authors: Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S
• Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase Ha study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).
  Volume: 34
  05/20/2016 Authors: Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane SV
• Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.
  Volume: 34
  05/20/2016 Authors: Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Maly JJ; Blum KA; Grover NS; Mathews S; Park SI; Gordon M
• Deferred treatment as a viable option for selected patients with mantle cell lymphoma.
  Volume: 34
  05/20/2016 Authors: Calzada O; Switchenko JM; Maly JJ; Blum KA; Grover NS; Mathews S; Park SI; Gordon MJ; Danilov AV; Flowers C
• Postibrutinib outcomes in patients with mantle cell lymphoma.
  Volume: 127 Page(s): 1559 - 1563
  03/24/2016 Authors: Martin P; Maddocks K; Leonard JP; Ruan J; Goy A; Wagner-Johnston N; Rule S; Advani R; Iberri D; Phillips T
• NONINVASIVE HIGH-RESOLUTION VISUALIZATION AND QUANTIFICATION OF DYNAMIC BLOOD FLOW IN GATED HUMAN SKIN MICROVESSLES
  Volume: 24 Page(s): A20 - A20
  03/01/2016 Authors: Pal D; Gnyawali C; Blum K; Ghatak S; Khanna S; Roy S; Sen K
• Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
  Leukemia Volume: 30 Page(s): 346 - 350
  02/01/2016 Authors: Rogers KA; Ruppert AS; Bingman A; Andritsos LA; Awan FT; Blum KA; Flynn JM; Jaglowski SM; Lozanski G; Maddocks KJ
• A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
  Volume: 54 Page(s): 11 - 17
  02/01/2016 Authors: Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F
• How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant.
  Blood Volume: 127 Page(s): 287 - 295
  01/21/2016 Authors: Alinari L; Blum KA
• Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403
  Volume: 126
  12/03/2015 Authors: Kaplan LD; Jung S-H; Stock W; Bartlett NL; Pitcher B; Byrd JC; Blum KA; LaCasce AS; Fulton N; Hsi ED
• Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL
  Volume: 126
  12/03/2015 Authors: O'Brien S; Jaglowski S; Byrd JC; Bannerji R; Blum K; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M
• Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma
  Volume: 126
  12/03/2015 Authors: Chen R; Li H; Bernstein SH; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS
• A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
  Volume: 126
  12/03/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston A; Flowers C; Devine SM; Blum KA
• A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)
  Volume: 126
  12/03/2015 Authors: Maddocks KJ; Cohen JB; Christian BA; Benson DM; Blum KA
• Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
  J Clin Oncol Volume: 33 Page(s): 3635 - 3640
  11/01/2015 Authors: Leonard JP; Jung S-H; Johnson J; Pitcher BN; Bartlett NL; Blum KA; Czuczman M; Giguere JK; Cheson BD
• Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.
  Br J Haematol Volume: 171 Page(s): 530 - 538
  11/01/2015 Authors: Diefenbach CS; Li H; Hong F; Gordon LI; Fisher RI; Bartlett NL; Crump M; Gascoyne RD; Wagner H; Stiff PJ
• Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study
  Volume: 38 Page(s): 18 - 19
  10/01/2015 Authors: Dreyling M; Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE
• Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
  Am J Hematol Volume: 90 Page(s): 778 - 783
  09/01/2015 Authors: Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ
• Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
  Blood Volume: 126 Page(s): 842 - 850
  08/13/2015 Authors: Jaglowski SM; Jones JA; Nagar V; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Smucker K
• Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
  Blood Volume: 126 Page(s): 739 - 745
  08/06/2015 Authors: Wang ML; Blum KA; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME
• Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
  Nat Med Volume: 21 Page(s): 922 - 926
  08/01/2015 Authors: Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih C-J; Williams PM; Shaffer AL; Gerecitano J
• Long-term treatment with single-agent ibrutinib 420 mg leads to durable responses including complete responses in CLL
  Volume: 75
  08/01/2015 Authors: Coutre S; Furman R; Flinn I; Burger J; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema N
• Hypermorphic mutation of phospholipase C, 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
  Blood Volume: 126 Page(s): 61 - 68
  07/02/2015 Authors: Liu T-M; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA
• Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
  J Clin Oncol Volume: 33 Page(s): 1936 - 1942
  06/10/2015 Authors: Advani RH; Hong F; Fisher RI; Bartlett NL; Robinson KS; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA
• Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
  Volume: 15 Page(s): S206 - S207
  06/01/2015 Authors: Jaglowski SM; Jones JA; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Greyer MR; Geyer SM; Heerema NA
• A PHASE IIA STUDY OF SINGLE- AGENT MOR208, AN FC-OPTIMIZED ANTI-CD19 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
  Volume: 100 Page(s): 395 - 396
  06/01/2015 Authors: Jurczak W; Zinzani PL; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Korolkiewicz R; Winderlich M
• The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
  Br J Haematol Volume: 169 Page(s): 701 - 710
  06/01/2015 Authors: Christian BA; Poi M; Jones JA; Porcu P; Maddocks K; Flynn JM; Benson DM; Phelps MA; Wei L; Byrd JC
• Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)
  Volume: 15 Page(s): S206 - S206
  06/01/2015 Authors: O'Brien SM; Jones JA; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum KA; Sharman JP; Wierda WG; Zhao W
• A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin's lymphoma
  Volume: 33
  05/20/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston AA; Flowers C; Devine SM; Blum KA
• Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
  Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 278 - 285.e1
  05/01/2015 Authors: Cohen JB; Ruppert AS; Heerema NA; Andritsos LA; Jones JA; Porcu P; Baiocchi R; Christian BA; Byrd JC; Flynn J
• Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
  Clin Pharmacol Ther Volume: 97 Page(s): 469 - 477
  05/01/2015 Authors: Alinari L; Quinion C; Blum KA
• Hodgkin lymphoma, version 2.2015.
  J Natl Compr Canc Netw Volume: 13 Page(s): 554 - 586
  05/01/2015 Authors: Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Aoun P; Bello CM; Benitez CM; Bierman PJ; Blum KA; Chen R
• Three-year follow-up of treatment-nave and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
  Blood Volume: 125 Page(s): 2497 - 2506
  04/16/2015 Authors: Byrd JC; Furman RR; Coutre SE; Burger JA; Blum KA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA
• Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-hodgkin lymphoma (iNHL)
  Volume: 169 Page(s): 54 - 54
  04/01/2015 Authors: Davies A; Salles G; Wagner-Johnston N; Kahl B; De Vos S; Schuster S; Jurczak W; Flinn I; Flowers C; Martin P
• Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
  JAMA Oncol Volume: 1 Page(s): 80 - 87
  04/01/2015 Authors: Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL
• Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
  Am J Hematol Volume: 90 Page(s): 327 - 333
  04/01/2015 Authors: Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA
• Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
  Leuk Lymphoma Volume: 56 Page(s): 958 - 964
  04/01/2015 Authors: Morrison VA; Jung S-H; Johnson J; LaCasce A; Blum KA; Bartlett NL; Pitcher BN; Cheson BD
• A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
  Leuk Lymphoma Volume: 56 Page(s): 1043 - 1049
  04/01/2015 Authors: Hofmeister CC; Williams N; Geyer S; Hade EM; Bowers MA; Earl CT; Vaughn J; Bingman A; Humphries K; Lozanski G
• A phase 1 dose-escalation study of XmAb 2513 in patients with relapsed or refractory Hodgkin lymphoma.
  Br J Haematol Volume: 168 Page(s): 902 - 904
  03/01/2015 Authors: Kumar A; Blum KA; Fung HC; Smith MR; Foster PA; Younes A
• CD30: seeing is not always believing.
  Blood Volume: 125 Page(s): 1358 - 1359
  02/26/2015 Authors: Blum KA
• A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
  Blood Volume: 125 Page(s): 242 - 248
  01/08/2015 Authors: Maddocks K; Christian B; Jaglowski S; Flynn J; Jones JA; Porcu P; Wei L; Jenkins C; Lozanski G; Byrd JC
• B-cell receptor pathway modulators in NHL.
  Hematology Am Soc Hematol Educ Program Volume: 2015 Page(s): 82 - 91
  01/01/2015 Authors: Blum KA
• Treatment strategies in mantle cell lymphoma.
  Cancer Treat Res Volume: 165 Page(s): 251 - 270
  01/01/2015 Authors: Maddocks K; Blum KA
• A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
  Volume: 124
  12/06/2014 Authors: Christian B; Wei L; Sexton J; Jaglowski SM; Devine SM; Fehniger TA; Wagner-Johnston N; Bartlett NL; Blum KA
• Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study
  Volume: 124
  12/06/2014 Authors: Wang M; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani R; Romaguera JE; Williams ME
• A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)
  BLOOD Volume: 124
  12/06/2014 Authors: Maddocks KJ; Cohen JB; Christian B; Flynn JM; Jaglowski SM; Blum KA
• Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
  Volume: 124
  12/06/2014 Authors: Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak W; Flinn IW; Flowers CR; Martin P; Viardot A
• A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
  Volume: 124
  12/06/2014 Authors: Blum KA; Maddocks K; Nagy Z; Zinzani PL; Goy A; Provencio M; Robak T; Buske C; Korolkiewicz RP; Winderlich M
• Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma
  Volume: 124
  12/06/2014 Authors: Martin P; Maddocks KJ; Noto K; Christian B; Furman RR; Andritsos LA; Flynn JM; Jones JA; Ruan J; Chen-Kiang S
• Poor Prognostic Effect of CD5 Positivity for Patients with Diffuse Large B-Cell Lymphoma: Results from a Retrospective Single Institution Analysis
  Volume: 124
  12/06/2014 Authors: Alinari L; Gru A; Quinion C; Huang Y; Jones JA; Devine SM; Maddocks KJ; Christian B; Baiocchi RA; Blum KA
• Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib
  Volume: 124
  12/06/2014 Authors: Rogers KA; Woyach JA; Andritsos LA; Awan F; Blum KA; Flynn JM; Jaglowski S; Lozanski G; Maddocks KJ; Byrd JC
• Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
  Blood Volume: 124 Page(s): 2354 - 2361
  10/09/2014 Authors: Petrich AM; Gandhi M; Jovanovic B; Castillo JJ; Rajguru S; Yang DT; Shah KA; Whyman JD; Lansigan F; Hernandez-Ilizaliturri FJ
• Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell Non-Hodgkin Lymphoma (iNHL)
  ONCOLOGY RESEARCH AND TREATMENT Volume: 37 Page(s): 185 - 185
  10/01/2014 Authors: Dreyling MH; Viardot A; Salles G; Wagner-Johnston ND; Kahl BS; De Vos S; Schuster SJ; Jurczak W; Flinn IW; Flowers C
• Updated phase 2 safety analysis of prevalence of infection, diarrhea, and bleeding with ibrutinib over time in previously treated mantle cell lymphoma
  Volume: 37 Page(s): 34 - 35
  10/01/2014 Authors: Stilgenbauer S; Rule S; Wang ML; Martin P; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera J; Williams M
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
  N Engl J Med Volume: 370 Page(s): 2286 - 2294
  06/12/2014 Authors: Woyach JA; Furman RR; Liu T-M; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH-H; Steggerda SM; Versele M
• PATIENT-REPORTED OUTCOMES DATA FROM A PHASE 2 STUDY OF IDELALISIB IN PATIENTS WITH REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (INHL)
  Volume: 99 Page(s): 143 - 143
  06/01/2014 Authors: Salles G; Wagner-Johnston ND; Kahl BS; De Vos S; Schuster SJ; Jurczak W; Flinn IW; Flowers C; Martin P; Viardot A
• PHASE 2 STUDY OF IBRUTINIB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED SAFETY ANALYSIS ON PREVALENCE OF INFECTION, DIARRHEA, AND BLEEDING OVER TIME
  Volume: 99 Page(s): 150 - 150
  06/01/2014 Authors: Rule S; Wang ML; Martin P; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera J; Williams M; Barrientos JC
• Ibrutinib in B-cell Lymphomas.
  Curr Treat Options Oncol Volume: 15 Page(s): 226 - 237
  06/01/2014 Authors: Maddocks K; Blum KA
• Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
  Cancer Volume: 120 Page(s): 1677 - 1685
  06/01/2014 Authors: Cohen JB; Geyer SM; Lozanski G; Zhao W; Heerema NA; Hall NC; Nagar VA; Hemminger JA; Jones JA; Porcu P
• DISEASE PROGRESSION ON IBRUTINIB THERAPY IS UNCOMMON AND IS ASSOCIATED WITH THE ACQUISITION OF RESISTANCE MUTATIONS: A SINGLE CENTER EXPERIENCE OF 267 PATIENTS
  Volume: 99 Page(s): 521 - 521
  06/01/2014 Authors: Maddocks K; Ruppert AS; Lozanski G; Lozanski A; Heerema NA; Heerema NA; Heerema NA; Abruzzo L; Gordon A; Jones JA
• Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non Hodgkin lymphoma (iNHL)
  Volume: 32
  05/20/2014 Authors: Wagner-Johnston ND; Gopal AK; Kahl BS; De Vos S; Schuster SJ; Jurczak W; Flinn I; Flowers C; Martin P; Viardot A
• Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.
  Volume: 32
  05/20/2014 Authors: O'Brien SM; Furman RR; Coutre SE; Flinn I; Burger JA; Blum KA; Sharman JP; Jones JA; Wierda WG; Zhao W
• CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.
  Volume: 32
  05/20/2014 Authors: Martin P; Jung S-H; Johnson JL; Pitcher B; Elstrom RL; Bartlett N; Blum KA; Richards KL; Leonard J; Cheson BD
• Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients.
  Volume: 32
  05/20/2014 Authors: Woyach JA; Ruppert AS; Lozanski G; Lozanski A; Heerema NA; Zhao W; Abruzzo L; Gordon A; Jones JA; Flynn JM
• A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
  Volume: 32
  05/20/2014 Authors: Jaglowski SM; Jones JA; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Geyer SM; Heerema NA
• Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL)
  Volume: 165 Page(s): 2 - 2
  05/01/2014 Authors: Davies A; Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Dansey R
• Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10002.
  Br J Haematol Volume: 165 Page(s): 102 - 111
  04/01/2014 Authors: Rizzieri DA; Johnson JL; Byrd JC; Lozanski G; Blum KA; Powell BL; Shea TC; Nattam S; Hoke E; Cheson BD
• PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma.
  N Engl J Med Volume: 370 Page(s): 1008 - 1018
  03/13/2014 Authors: Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A
• Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
  Lancet Oncol Volume: 15 Page(s): 48 - 58
  01/01/2014 Authors: O'Brien S; Furman RR; Coutre SE; Sharman JP; Burger JA; Blum KA; Grant B; Richards DA; Coleman M; Wierda WG
• Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.
  Am J Hematol Volume: 89 Page(s): 19 - 24
  01/01/2014 Authors: Jones JA; Rupert AS; Poi M; Phelps MA; Andritsos L; Baiocchi R; Benson DM; Blum KA; Christian B; Flynn J
• Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
  Volume: 122
  11/15/2013 Authors: Gopal A; Kahl BS; De Vos S; Wagner-Johnston ND; Schuster SJ; Blum KA; Jurczak WJ; Flinn IW; Flowers CR; Martin P
• Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
  J Clin Oncol Volume: 31 Page(s): 4132 - 4139
  11/10/2013 Authors: Evens AM; Advani R; Press OW; Lossos IS; Vose JM; Hernandez-Ilizaliturri FJ; Robinson BK; Otis S; Nadav Dagan L; Abdallah R
• Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.
  Bone Marrow Transplant Volume: 48 Page(s): 1212 - 1217
  09/01/2013 Authors: Cohen JB; Hall NC; Ruppert AS; Jones JA; Porcu P; Baiocchi R; Christian BA; Penza S; Benson DM; Flynn J
• Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
  Leuk Lymphoma Volume: 54 Page(s): 1996 - 2002
  09/01/2013 Authors: Walker AR; Klisovic R; Johnston JS; Jiang Y; Geyer S; Kefauver C; Binkley P; Byrd JC; Grever MR; Garzon R
• Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
  N Engl J Med Volume: 369 Page(s): 507 - 516
  08/08/2013 Authors: Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
  N Engl J Med Volume: 369 Page(s): 32 - 42
  07/04/2013 Authors: Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum KA; Grant B; Sharman JP; Coleman M; Wierda WG
• UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
  Volume: 98 Page(s): 489 - 489
  06/12/2013 Authors: Rule S; Wang M; Martin P; Auer R; Kahl B; Jurczak W; Advani R; Romaguera J; Williams M; Barrientos J
• A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
  Clin Cancer Res Volume: 19 Page(s): 1269 - 1280
  03/01/2013 Authors: Ji J; Mould DR; Blum KA; Ruppert AS; Poi M; Zhao Y; Johnson AJ; Byrd JC; Grever MR; Phelps MA
• Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
  J Clin Oncol Volume: 31 Page(s): 684 - 691
  02/20/2013 Authors: Gordon LI; Hong F; Fisher RI; Bartlett NL; Connors JM; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Gospodarowicz M
• Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)
  Volume: 120
  11/16/2012 Authors: Morrison VA; Jung S-H; Johnson J; LaCasce A; Blum KA; Bartlett NL; Cheson BD
• A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
  Volume: 120
  11/16/2012 Authors: Fehniger TA; Larson S; Trinkaus K; Siegel MJ; Hurd DD; Blum KA; Goy A; Fenske TS; Cashen A; Wagner-Johnston ND
• A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)
  Volume: 120
  11/16/2012 Authors: Christian B; Kopko A; Fehniger TA; Bartlett NL; Blum KA
• A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
  Volume: 120
  11/16/2012 Authors: Blum KA; Christian B; Flynn JM; Jaglowski SM; Jones JA; Maddocks K; Byrd JC
• ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
  Blood Volume: 120 Page(s): 1262 - 1273
  08/09/2012 Authors: Mahoney E; Lucas DM; Gupta SV; Wagner AJ; Herman SEM; Smith LL; Yeh Y-Y; Andritsos L; Jones JA; Flynn JM
• Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.
  Leukemia Volume: 26 Page(s): 1442 - 1444
  06/01/2012 Authors: Woyach JA; Lozanski G; Ruppert AS; Lozanski A; Blum KA; Jones JA; Flynn JM; Johnson AJ; Grever MR; Heerema NA
• The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study.
  Volume: 30
  05/20/2012 Authors: Byrd JC; Furman RR; Coutre SE; Burger JA; Blum KA; Sharman JP; Flinn IW; Grant BW; Heerema NA; Johnson AJ
• CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma.
  Volume: 30
  05/20/2012 Authors: Leonard J; Jung S-H; Johnson JL; Bartlett N; Blum KA; Cheson BD
• Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL).
  Volume: 30
  05/20/2012 Authors: Stephens DM; Ruppert AS; Christian B; Jones JA; Flynn JM; Porcu P; Baiocchi RA; Byrd JC; Dotson EK; Crawford BS
• Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.
  J Natl Compr Canc Netw Volume: 10 Page(s): 589 - 597
  05/01/2012 Authors: Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Aoun P; Bello CM; Bierman PJ; Blum KA; Chen R; Dabaja B
• Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity
  Volume: 47 Page(s): S84 - S85
  04/01/2012 Authors: Salem G; Dunavin N; Wei L; Elder P; Penza S; Blum K; Porcu P; Baiocchi R; Jones J; Flynn J
• Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.
  Haematologica Volume: 97 Page(s): 423 - 427
  03/01/2012 Authors: Stephens DM; Ruppert AS; Blum K; Jones J; Flynn JM; Johnson AJ; Ji J; Phelps MA; Grever MR; Byrd JC
• COMPLEX KARYOTYPE (CK) IS ASSOCIATED WITH INCREASED CUMULATIVE INCIDENCE OF RELAPSE (CIR) FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MANTLE CELL LYMPHOMA (MCL) IN FIRST REMISSION
  Volume: 18 Page(s): S205 - S206
  02/01/2012 Authors: Cohen JB; Ruppert AS; Kaplan LD; Baiocchi R; Porcu P; Flynn J; Penza S; Jones JA; Blum KA; Devine SM
• FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
  Blood Volume: 118 Page(s): 6893 - 6903
  12/22/2011 Authors: Alinari L; Mahoney E; Patton J; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Quinion C
• Evaluation and management of lymphoma and leukemia in pregnancy.
  Clin Obstet Gynecol Volume: 54 Page(s): 556 - 566
  12/01/2011 Authors: Cohen JB; Blum KA
• The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma
  Volume: 118 Page(s): 1345 - 1346
  11/18/2011 Authors: Cohen JB; Hall N; Ruppert AS; Jones JA; Porcu P; Baiocchi RA; Penza S; Benson DM; Andritsos LA; Flynn JM
• Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
  Volume: 118 Page(s): 1584 - 1584
  11/18/2011 Authors: Christian B; Alinari L; Jones JA; Benson DM; Flynn JM; Porcu P; Lustberg ME; Phelps M; Poi M; Chung D
• The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study
  Volume: 118 Page(s): 449 - 450
  11/18/2011 Authors: O'Brien S; Burger JA; Blum KA; Furman RR; Coutre SE; Sharman J; Flinn IW; Grant B; Heerema NA; Johnson AJ
• Phase 1 Study of TRU-016, An Anti-CD37 SMIP (TM) Protein in Relapsed and/or Refractory NHL Patients
  Volume: 118 Page(s): 711 - 711
  11/18/2011 Authors: Pagel JM; Spurgeon S; Awan F; Blum KA; Lanasa MC; Flinn IW; Stromatt S; Byrd JC; Gopal AK
• Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial
  Volume: 118 Page(s): 1672 - 1672
  11/18/2011 Authors: Blum KA; Wei L; Jones JA; Andritsos LA; Flynn JM; Heerema NA; Yang X; Rozewski D; Phelps M; Johnson AJ
• FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death
  Volume: 118 Page(s): 275 - 276
  11/18/2011 Authors: Alinari L; Mahoney E; Patton JT; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Towns WH
• The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial
  Volume: 118 Page(s): 203 - 204
  11/18/2011 Authors: Wang L; Martin P; Blum KA; Kahl BS; Maeda LS; Advani R; Williams ME; Rule S; Rodriguez S; Pang C-F
• Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496
  Volume: 118 Page(s): 696 - 697
  11/18/2011 Authors: Advani R; Hong F; Gordon LI; Gascoyne RD; Wagner H; Hoppe RT; Fisher RI; Bartlett NL; Kahl BS; Stiff P
• A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
  Blood Volume: 118 Page(s): 5119 - 5125
  11/10/2011 Authors: Fehniger TA; Larson S; Trinkaus K; Siegel MJ; Cashen AF; Blum KA; Fenske TS; Hurd DD; Goy A; Schneider SE
• Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
  Leukemia Volume: 25 Page(s): 1444 - 1451
  09/01/2011 Authors: Blum KA; Ruppert AS; Woyach JA; Jones JA; Andritsos L; Flynn JM; Rovin B; Villalona-Calero M; Ji J; Phelps M
• Hodgkin lymphoma.
  J Natl Compr Canc Netw Volume: 9 Page(s): 1020 - 1058
  09/01/2011 Authors: Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Bello CM; Bierman PJ; Blum KA; Dabaja B; Duron Y; Forero A
• Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
  Blood Volume: 117 Page(s): 6287 - 6296
  06/09/2011 Authors: Herman SEM; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ
• Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
  Cancer Volume: 117 Page(s): 2442 - 2451
  06/01/2011 Authors: Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
• THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND TOLERABLE IN PATIENTS WITH POOR-RISK CLL: INTERIM RESULTS FROM A PHASE IB/II STUDY
  Volume: 22 Page(s): 124 - 124
  06/01/2011 Authors: O'Brien S; Burger JA; Coutre SE; Sharman JP; Furman RR; Flinn IW; Grant B; Richards D; Heerema N; Johnson AJ
• Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL.
  Volume: 29
  05/20/2011 Authors: Flynn JM; Jones JA; Andritsos L; Blum KA; Johnson AJ; Hessler J; Wiley E; Heerema NA; Poon J; Small KA
• Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study
  Volume: 29
  05/20/2011 Authors: Byrd JC; Blum KA; Burger JA; Coutre SE; Sharman JP; Furman RR; Flinn IW; Grant BW; Richards DA; Zhao W
• Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
  Blood Volume: 117 Page(s): 4530 - 4541
  04/28/2011 Authors: Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X
• The role of phosphatidylinositol 3-kinase- in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
  Blood Volume: 117 Page(s): 4323 - 4327
  04/21/2011 Authors: Herman SEM; Lapalombella R; Gordon AL; Ramanunni A; Blum KA; Jones J; Zhang X; Lannutti BJ; Puri KD; Muthusamy N
• A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
  Volume: 116 Page(s): 1148 - 1149
  11/19/2010 Authors: Christian B; Alinari L; Earl CT; Wilding E; Quinion C; Lustberg M; Benson DM; Jones JA; Byrd JC; Wegener WA
• Response, Progression-Free Survival, and Overall Survival of patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities
  Volume: 116 Page(s): 1019 - 1020
  11/19/2010 Authors: Woyach JA; Ruppert AS; Blum KA; Jones JA; Flynn JM; Johnson AJ; Grever MR; Byrd JC; Heerema NA
• A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)
  Volume: 116 Page(s): 185 - 185
  11/19/2010 Authors: Gordon LI; Hong F; Fisher RI; Bartlett NL; Connors JM; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Gospodarowicz M
• The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies
  Volume: 116 Page(s): 32 - 32
  11/19/2010 Authors: Burger JA; O'Brien S; Fowler N; Advani R; Sharman JP; Furman RR; Izumi R; Buggy J; Loury D; Hamdy A
• Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol
  Volume: 116 Page(s): 596 - 597
  11/19/2010 Authors: Blum KA; Ruppert AS; Woyach JA; Jones JA; Andritsos L; Flynn JM; Rovin B; Villalona-Calero M; Ji J; Phelps M
• Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma
  Volume: 116 Page(s): 1169 - 1169
  11/19/2010 Authors: Jones JA; Andritsos L; Baiocchi R; Benson DM; Blum KA; Christian B; Deam D; Flynn JM; Johnson AJ; Phelps MA
• Randomized Phase III Trial Comparing ABVD plus Radiotherapy and the Stanford V.Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A-Subset Analysis of the US Intergroup Trial E2496
  Volume: 116 Page(s): 185 - 186
  11/19/2010 Authors: Advani R; Hong F; Fisher RI; Bartlett NL; Robinson S; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA
• Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration.
  Volume: 116 Page(s): 600 - 601
  11/19/2010 Authors: Flynn JM; Jones JA; Andritsos L; Blum KA; Johnson AJ; Hessler J; Wiley E; Poon J; Small K; Statkevich P
• Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma
  Volume: 116 Page(s): 147 - 147
  11/19/2010 Authors: Racke F; Simpson S; Christian B; Blum KA; Hasserjian R; Zhao W
• Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients
  Volume: 116 Page(s): 592 - 593
  11/19/2010 Authors: Stephens DM; Ruppert AS; Blum KA; Jones JA; Flynn JM; Johnson AJ; Ji J; Phelps M; Grever MR; Byrd JC
• Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)
  Volume: 116 Page(s): 1027 - 1027
  11/19/2010 Authors: Blum KA; Jones JA; Andritsos L; Flynn JM; Deam D; Heerema NA; Phelps M; Johnson AJ; Grever MR; Byrd JC
• Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcRIIIa-158 V/F polymorphism.
  Ann Oncol Volume: 21 Page(s): 2246 - 2254
  11/01/2010 Authors: Blum KA; Jung S-H; Johnson JL; Lin TS; Hsi ED; Lucas DM; Byrd JC; Cheson BD; Bartlett NL; Cancer and Leukemia Group B
• Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor.
  J Clin Oncol Volume: 28 Page(s): e629 - e632
  11/01/2010 Authors: Christian B; Zhao W; Hamadani M; Sotomayor EM; Navarro W; Devine SM; Racke F; Blum KA
• Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
  Br J Haematol Volume: 150 Page(s): 189 - 195
  07/01/2010 Authors: Blum KA; Liu Z; Lucas DM; Chen P; Xie Z; Baiocchi R; Benson DM; Devine SM; Jones J; Andritsos L
• The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.
  PLoS One Volume: 5 Page(s): e10941
  06/03/2010 Authors: Lucas DM; Alinari L; West DA; Davis ME; Edwards RB; Johnson AJ; Blum KA; Hofmeister CC; Freitas MA; Parthun MR
• Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
  Blood Volume: 115 Page(s): 2619 - 2629
  04/01/2010 Authors: Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA
• Two Short-Term Outcomes After Instituting a National Regulation Regarding Minimum Procedural Volumes for Total Knee Replacement
  JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME Volume: 92A Page(s): 629 - 638
  03/01/2010 Authors: Ohmann C; Verde PE; Blum K; Fischer B; de Cruppe W; Geraedts M
• Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.
  Br J Haematol Volume: 148 Page(s): 754 - 759
  03/01/2010 Authors: Woyach JA; Heerema NA; Zhao J; McFaddin A; Stark A; Lin TS; Andritsos LA; Blum KA; Flynn JM; Jones JA
• Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
  J Clin Oncol Volume: 28 Page(s): 418 - 423
  01/20/2010 Authors: Lin TS; Blum KA; Fischer DB; Mitchell SM; Ruppert AS; Porcu P; Kraut EH; Baiocchi RA; Moran ME; Johnson AJ
• Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphoma.
  Hematology Am Soc Hematol Educ Program Volume: 2010 Page(s): 93 - 100
  01/01/2010 Authors: Blum KA
• Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
  Volume: 27 Page(s): 6101 - 6108
  12/20/2009 Authors: Damon LE; Johnson JL; Niedzwiecki D; Cheson BD; Hurd DD; Bartlett NL; Lacasce AS; Blum KA; Byrd JC; Kelly M
• Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
  J Clin Oncol Volume: 27 Page(s): 6012 - 6018
  12/10/2009 Authors: Lin TS; Ruppert AS; Johnson AJ; Fischer B; Heerema NA; Andritsos LA; Blum KA; Flynn JM; Jones JA; Hu W
• A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.
  Volume: 114 Page(s): 1422 - 1422
  11/20/2009 Authors: Fehniger TA; Larson S; Trinkaus K; Siegel MJ; Cashen AF; Blum KA; Fenske TS; Hurd DD; Goy A; DiPersio JF
• Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease
  Volume: 114 Page(s): 508 - 508
  11/20/2009 Authors: Woyach JA; Byrd JC; Zhao J; McFaddin A; Ruppert AS; Lin TS; Andritsos L; Blum KA; Flynn JM; Jones JA
• Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.
  Volume: 114 Page(s): 1339 - 1339
  11/20/2009 Authors: Maddocks K; Lapalombella R; Blum KA; Blum W; Fischer BB; Muthusamy N; Moran ME; Holtzapfel D; Byrd JC; Johnson AJ
• Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.
  Br J Haematol Volume: 147 Page(s): 507 - 514
  11/01/2009 Authors: Blum KA; Advani A; Fernandez L; Van Der Jagt R; Brandwein J; Kambhampati S; Kassis J; Davis M; Bonfils C; Dubay M
• Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy
  Volume: 27
  05/20/2009 Authors: Blum KA; Smith M; Fung H; Zalevsky J; Combs D; Ramies DA; Younes A
• Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
  Biol Blood Marrow Transplant Volume: 15 Page(s): 547 - 553
  05/01/2009 Authors: Hamadani M; Benson DM; Hofmeister CC; Elder P; Blum W; Porcu P; Garzon R; Blum KA; Lin TS; Marcucci G
• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
  Blood Volume: 113 Page(s): 2637 - 2645
  03/19/2009 Authors: Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM
• Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.
  Leuk Lymphoma Volume: 50 Page(s): 349 - 356
  03/01/2009 Authors: Blum KA; Hamadani M; Phillips GS; Lozanski G; Johnson AJ; Lucas DM; Smith LL; Baiocchi R; Lin TS; Porcu P
• FEASIBILITY OF ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (ALLO-SCT) FOLLOWING REDUCED INTENSITY CONDITIONING (RIC) IN HIV plus PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
  Volume: 15 Page(s): 113 - 113
  02/01/2009 Authors: Hamadani M; Baiocchi R; Lin T; Blum KA; Ezzone S; Benson DM; Devine SM; Arthur G
• ALLOGENEIC VERSUS AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR FOLLICULAR LYMPHOMA (FL). THE JAMES COMPREHENSIVE CANCER CENTER EXPERIENCE
  Volume: 15 Page(s): 132 - 132
  02/01/2009 Authors: Grauer A; Hamadani M; Blum KA; Porcu P; Benson DM; Devine SM
• Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
  MAbs Volume: 1 Page(s): 31 - 40
  01/01/2009 Authors: Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P
• High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.
  Eur J Haematol Volume: 81 Page(s): 425 - 431
  12/01/2008 Authors: Hamadani M; Benson DM; Lin TS; Porcu P; Blum KA; Devine SM
• A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation
  Volume: 112 Page(s): 1087 - 1087
  11/16/2008 Authors: Blum KA; Liu Z; Lucas DM; Baiocchi R; Lin TS; Benson D; Devine SM; Jones J; Andritsos L; Flynn J
• Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas
  Volume: 112 Page(s): 1121 - 1121
  11/16/2008 Authors: Hamadani M; Blum KA; Elder P; Lin TS; Porcu P; Hofmeister CC; Blum W; Marcucci G; Benson D; Devine S
• A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma
  Volume: 112 Page(s): 1049 - 1050
  11/16/2008 Authors: Blum KA; Baiocchi RA; Alinari L; Lin TS; Porcu P; Jones J; Flynn J; Hicks W; Lucas MS; Wei L
• Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma
  Volume: 112 Page(s): 557 - 558
  11/16/2008 Authors: Lin TS; Fischer B; Blum KA; Porcu P; Kraut EH; Baiocchi RA; Moran ME; Mitchell S; Grever MR; Byrd JC
• A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results.
  Volume: 112 Page(s): 899 - 900
  11/16/2008 Authors: Fehniger TA; Larson S; Trinkaus K; Siegel MJ; DiPersio JF; Cashen AF; Hurd DD; Blum KA; Bartlett NL
• Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinoreibine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502
  Volume: 112 Page(s): 92 - 93
  11/16/2008 Authors: Blum KA; Johnson JL; Jung S-H; Cheson BD; Bartlett NL
• Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.
  Volume: 49 Page(s): 1893 - 1898
  10/01/2008 Authors: Hamadani M; Awan FT; Elder P; Lin TS; Porcu P; Benson DM; Blum KA; Devine SM
• Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
  Ther Drug Monit Volume: 30 Page(s): 620 - 627
  10/01/2008 Authors: Liu Q; Farley KL; Johnson AJ; Muthusamy N; Hofmeister CC; Blum KA; Schaaf LJ; Grever MR; Byrd JC; Dalton JT
• Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
  J Chromatogr B Analyt Technol Biomed Life Sci Volume: 871 Page(s): 15 - 21
  08/01/2008 Authors: Johnston JS; Phelps MA; Blum KA; Blum W; Grever MR; Farley KL; Dalton JT
• Hodgkin disease/lymphoma.
  J Natl Compr Canc Netw Volume: 6 Page(s): 594 - 622
  07/01/2008 Authors: Hoppe RT; Advani RH; Ambinder RF; Bierman PJ; Bloomfield CD; Blum K; Dabaja B; Djulbegovic B; Forero A; Gordon LI
• Comparison of allogeneic vs. autologous transplantation for follicular lymphoma after transformation into diffuse large B-cell lymphoma
  Volume: 26
  05/20/2008 Authors: Awan FT; Hamadani M; Lin TS; Porcu P; Blum KA; Benson DM; Devine SM
• Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)
  Volume: 26
  05/20/2008 Authors: Lin TS; Andritsos LA; Jones JA; Fischer B; Heerema NA; Blum KA; Flynn JM; Moran ME; Phelps MA; Grever MR
• Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect.
  Biol Blood Marrow Transplant Volume: 14 Page(s): 480 - 483
  04/01/2008 Authors: Hamadani M; Awan FT; Elder P; Lin TS; Porcu P; Blum KA; Devine SM
• Chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetics respond to treatment with flavopiridol: Study of 120 patients (pts) with relapsed, genetically high risk CLL
  Volume: 121
  01/01/2008 Authors: Heerema NA; Lin TS; Fischer B; Lozanski G; Blum KA; Andritsos LA; Jones JA; Flynn JM; Moran ME; Mitchell SM
• Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.
  J Clin Oncol Volume: 25 Page(s): 5624 - 5629
  12/10/2007 Authors: Blum KA; Young D; Broering S; Lucas MS; Fischer B; Lin TS; Grever MR; Byrd JC
• Del(17p13.1) in chronic lympliucytic leukemia confers poor prognosis even at low percentage involvement and increases proportionately with. increase in clonal involvement
  Volume: 110 Page(s): 617A - 618A
  11/16/2007 Authors: Andritsos LA; Jones J; Lozanski G; Lin TS; Blum KA; Grever MR; Jarjoura D; Byrd JC; Heerema N
• Clinical activity of flavopiridol in relapsed and refractory chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities: Updated data on 89 patients (Pts).
  Volume: 110 Page(s): 914A - 914A
  11/16/2007 Authors: Heerema NA; Byrd JC; Andritsos LA; Lozanski G; Blum K; Fischer B; Jones JA; Moran ME; Groering S; Schaaf LJ
• A phase I trial of subcutaneous (SQ) dose-escalated alemtuzumab in patients with T-Cell lymphoproliferative disorders (T-LPD)
  Volume: 110 Page(s): 1001A - 1001A
  11/16/2007 Authors: Porcu P; Baiocchi RA; Lin TS; Blum KA; Curtis P; Michael GR; Byrd JC
• High rates of early donor chimerism and low risk of chronic GVHD can be achieved in poor risk patients undergoing unrelated donor stem cell transplantation using a reduced intensity conditioning regimen incorporating fludarabine, busulfan, and rabbit ATG
  Volume: 110 Page(s): 351B - 351B
  11/16/2007 Authors: Hamadani M; Elder P; Awan F; Krugh D; Blum W; Lin T; Andritsos L; Bechtel T; Blum K; Klisovic R
• Low incidence of opportunistic infections in CLL patients treated with single agent flavopiridol
  Volume: 110 Page(s): 920A - 920A
  11/16/2007 Authors: Andritsos LA; Fischer B; Lin TS; Blum KA; Jones JA; Moran ME; Byrd JC; Grever MR
• Preliminary results of a phase II study of flavopiridol (Alvocidib) in, relapsed chronic lymphocytic leukemia (CLL): Confirmation of clinical activity in high-risk patients and achievement of complete responses (CR).
  Volume: 110 Page(s): 913A - 913A
  11/16/2007 Authors: Lin TS; Fischer B; Blum KA; Andritsos LA; Jones JA; Moran ME; Broering S; Heerema NA; Lozanski G; Schaaf LJ
• Allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma: Evidence of graft-versus-lymphoma effect
  Volume: 110 Page(s): 894A - 894A
  11/16/2007 Authors: Awan F; Elder P; Porcu P; Lin T; Blum K; Scholl D; Devine SM
• Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
  Leuk Lymphoma Volume: 48 Page(s): 1313 - 1319
  07/01/2007 Authors: Blum KA; Johnson JL; Niedzwiecki D; Canellos GP; Cheson BD; Bartlett NL
• Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
  Blood Volume: 109 Page(s): 399 - 404
  01/15/2007 Authors: Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M
• Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
  Cancer Volume: 107 Page(s): 2817 - 2825
  12/15/2006 Authors: Blum KA; Johnson JL; Niedzwiecki D; Piro LD; Saven A; Peterson BA; Byrd JC; Cheson BD; Cancer and Leukemia Group B Study 9153
• Flavopiridol can be safely dose escalated in relapsed CLL patients: Achievement of target C-max results in improved clinical activity.
  Volume: 108 Page(s): 805A - 806A
  11/16/2006 Authors: Lin TS; Phelps M; Dalton JT; Fischer B; Blum KA; Moran ME; McEldowney MB; Broering S; Colevas D; Byrd JC
• Flavopiridol is active in genetically high-risk, relapsed chronic lymphocytic leukemia (CLL): Analysis of 56 patients by cytogenetic abnormality.
  Volume: 108 Page(s): 93A - 93A
  11/16/2006 Authors: Lin TS; Heerema NA; Fischer B; Blum KA; Moran ME; McEldowney MB; Broering S; Lozanski G; Colevas D; Grever MR
• The addition of CT scans to NCI-96 chronic lymphocytic leukemia (CLL) response criteria pails to improve the predictive power of complete response (CR) and partial response (PR) as assessed by improvement in progression-free (PFS) and overall survival (OS).
  Volume: 108 Page(s): 802A - 802A
  11/16/2006 Authors: Blum KA; Young D; Broering S; Lucas MS; Lin TS; Grever MR; Byrd JC
• Excessive neurotoxicity in a phase II trial of combined bortezomib and rituximab in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma.
  Volume: 108 Page(s): 784A - 784A
  11/16/2006 Authors: Blum KA; Lucas MS; Johnston JS; Dalton J; Young D; Baiocchi RA; Lin TS; Porcu P; Byrd JC
• Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: Preliminary results.
  Volume: 24 Page(s): 445S - 445S
  06/20/2006 Authors: Porcu P; Baiocchi RA; Lee J; Lin TS; Blum K; Grady T; Grever MR; Byrd JC
• A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206.
  Volume: 24 Page(s): 440S - 440S
  06/20/2006 Authors: Blum KA; Johnson JL; Niedzwiecki D; Cannellos GP; Cheson BD; Bartlett NL
• Flavopiridol, fludarabine and rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL).
  Volume: 24 Page(s): 446S - 446S
  06/20/2006 Authors: Lin TS; Fischer B; Moran ME; Shank RS; Kraut E; Porcu P; Farag SS; Blum KA; Colevas AD; Grever MR
• Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high risk chronic lymphocytic leukemia (CLL).
  Volume: 24 Page(s): 341S - 341S
  06/20/2006 Authors: Byrd JC; Lin TS; Dalton JT; Phelps M; Fischer B; Moran M; Blum K; Rovin B; Colevas AD; Grever MR
• Successful management (Mgt) of hyperkalemia associated with tumor lysis syndrome (TLS) in refractory chronic lymphocytic leukemia (CLL) patients (pts) receiving flavopiridol on an active pharmacologically derived schedule.
  Volume: 106 Page(s): 600A - 601A
  11/16/2005 Authors: Moran ME; Fischer B; Broering S; Blum KA; Lin TS; Byrd JC; Grever MR; Brooker-McEldowney M
• Combination bortezomib (PS341, Velcade) and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
  Volume: 106 Page(s): 677A - 677A
  11/16/2005 Authors: Wadehra N; Lin T; Ryan T; Schneider A; Pepple A; Johnston J; Dalton J; Banks A; Eisenbeis CR; Lai R
• Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.
  Br J Cancer Volume: 93 Page(s): 46 - 53
  07/11/2005 Authors: Fracasso PM; Blum KA; Ma MK; Tan BR; Wright LP; Goodner SA; Fears CL; Hou W; Arquette MA; Picus J
• Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-HR continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL)
  Volume: 16 Page(s): 65 - 65
  06/01/2005 Authors: Lin T; Blum K; Dalton J; Wu D; Fischer B; Moran M; Johnson A; Lucas D; Heerema N; Lozanski G
• Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
  J Clin Oncol Volume: 22 Page(s): 4561 - 4566
  11/15/2004 Authors: Hoerr AL; Gao F; Hidalgo J; Tiwari D; Blum KA; Mathews V; Adkins DR; Blum W; Devine S; Vij R
• Adult Burkitt leukemia and lymphoma.
  Blood Volume: 104 Page(s): 3009 - 3020
  11/15/2004 Authors: Blum KA; Lozanski G; Byrd JC
• Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes.
  Bone Marrow Transplant Volume: 34 Page(s): 615 - 619
  10/01/2004 Authors: Hidalgo JD; Krone R; Rich MW; Blum K; Adkins D; Fan M-Y; Brown R; Devine S; Graubert T; Blum W
• 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
  Expert Opin Biol Ther Volume: 4 Page(s): 1323 - 1331
  08/01/2004 Authors: Blum KA; Bartlett NL
• Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
  J Clin Oncol Volume: 22 Page(s): 1071 - 1077
  03/15/2004 Authors: Tedesco KL; Thor AD; Johnson DH; Shyr Y; Blum KA; Goldstein LJ; Gradishar WJ; Nicholson BP; Merkel DE; Murrey D
• A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer.
  Cancer Biol Ther Volume: 3 Page(s): 89 - 93
  01/01/2004 Authors: Hobdy EM; Kraut E; Masters G; Blum K; McKeon A; Byrd B; Davies M; Beaulieu N; Murren JR
• Antibodies for the treatment of diffuse large cell lymphoma.
  Semin Oncol Volume: 30 Page(s): 448 - 456
  08/01/2003 Authors: Blum KA; Bartlett NL
• Risk factors for cardiac arrhythmias following autologous hematopoietic stem cell transplantation (HSCT) for non-Hodgkins lymphoma (NHL).
  Volume: 100 Page(s): 435B - 435B
  11/16/2002 Authors: Hidalgo J; Blum KA; Rich M; Krone R; Brown R; Devine S; Goodnough LT; Graubert T; Tomasson M; Vij R
• Impact of pre-transplant rituximab on early post-transplant complications in NHL.
  Volume: 100 Page(s): 435B - 435B
  11/16/2002 Authors: Hidalgo J; Adkins D; Blum KA; Brown R; Devine S; Mayfield J; Goodnough LT; Graubert T; Tomasson M; Vij R
• Delayed neutrophil and platelet engraftment following autologous transplantation in non-Hodgkins lymphoma patients previously treated with rituximab.
  Volume: 100 Page(s): 643A - 643A
  11/16/2002 Authors: Blum KA; Hidalgo J; Khoury H; Baty J; Brown RA; Adkins DR; DiPersio JF; Bartlett NL
• Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
  Cancer Volume: 95 Page(s): 2223 - 2229
  11/15/2002 Authors: Fracasso PM; Blum KA; Tan BR; Fears CL; Bartlett NL; Arquette MA; Clark RS
• Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
  CANCER BIOLOGY & THERAPY Volume: 1 Page(s): 646 - 651
  11/01/2002 Authors: Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR